scRNA and TCR-Seq of peripheral blood mononuclear cells (PBMC) from r/r classical Hodgkin Lymphoma patients under anti-PD1 therapy.. scRNA and TCR-Seq of peripheral blood mononuclear cells (PBMC) from r/r classical Hodgkin Lymphoma patients under anti-PD1 therapy.

We did scRNA and TCR-seq in order to determine the immunophenotic profile of refractory and relapsed patients under anti-PD1 therapy and evaluate based on their response. Overall design: PBMC were isolated from the blood of each patients. All samples wew sequenced at 3 different time-point: baseline, post cicle 5 and post cycle 9 of therapy.

本研究采用单细胞RNA测序（single-cell RNA sequencing, scRNA-seq）与T细胞受体测序（T-cell receptor sequencing, TCR-seq），旨在明确接受抗PD-1治疗的难治性及复发性患者的免疫表型谱，并基于其治疗应答情况开展评估。实验设计：从每名患者的血液中分离外周血单个核细胞（peripheral blood mononuclear cell, PBMC）；所有样本均在3个不同时间点完成测序：治疗基线期、第5个疗程后及第9个疗程后。